Brian Connolly, MD
Retina Specialist · Rochester, NYNPI 1164401741
Payments from drug & device makers
Across 284 payments — averaging $5955.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.6M
- Hexal AG$96K
- US Retina LLC$4K
- Roche TCRC, Inc.$3K
- Genentech USA, Inc.$665
- Regeneron Healthcare Solutions, Inc.$536
- plus $2K from 16 others
What the payments were for
- Food & beverage$3,02943%
- Education$381%
- Ownership interest$3,99557%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 156 | $1,585,358 |
| Hexal AG | 13 | $95,671 |
| US Retina LLC | 12 | $3,995 |
| Roche TCRC, Inc. | 1 | $3,200 |
| Genentech USA, Inc. | 18 | $665 |
| Regeneron Healthcare Solutions, Inc. | 14 | $536 |
| AbbVie | 15 | $367 |
| Astellas Pharma US Inc | 8 | $239 |
| Apellis Pharmaceuticals, Inc. | 6 | $234 |
| Eyepoint US, Inc. | 3 | $146 |
| Alimera Sciences, Inc. | 7 | $131 |
| Sandoz | 6 | $130 |
| ANI Pharmaceuticals, Inc. | 5 | $125 |
| Hoffmann-la Roche Limited | 1 | $125 |
| Coherus Oncology, Inc. | 5 | $116 |
| Harrow Eye, LLC | 2 | $64 |
| Novartis | 3 | $53 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Spark Therapeutics, Inc. | 2 | $31 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Alcon | 1 | $14 |
| Rapid Pathogen Screening, Inc. | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,691,253 in reported general payments places this provider in the 95th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 121 | $12,656 |
| Prednisolone Acetate | 246 | $11,299 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $5,338 |
| Difluprednate | 33 | $3,103 |
| Timolol Maleate | 49 | $910 |
| Latanoprost | 123 | $897 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 75 | $836 |
| Tobramycin | 177 | $824 |
| Brimonidine Tartrate | 91 | $752 |
| Ketorolac Tromethamine | 11 | $563 |
| ErythromycinErythromycin Base | 34 | $340 |
| Diclofenac Sodium | 15 | $151 |
| Prednisone | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Edward HallRochester$264K
- Matthew WitmerRochester$246K
- Steven RoseRochester$145K
- Vikas KhetanRochester$3K
- Sana IdreesRochester$2K
- Jamin BrownLiverpool$3.3M
- Paul HahnNanuet$1.1M
- Patrick OellersLiverpool$615K
- Naomi FalkSlingerlands$436K
- Szilard KissNew York$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.